Thera-T Pharmaceutics, Inc
MATCH provides a high-throughput platform for designing and screening bispecific antibody fragments that simultaneously target multiple antigens on B-cell leukemias, lymphomas, and multiple myeloma. The system integrates predictive modeling with rapid combinatorial antibody generation to create multi-specific immunotherapies aimed at improving T-cell activation while reducing cytokine release. The platform has been validated in peer-reviewed studies published in ACS Nano, Nanomedicine, and Nature Communications Biology.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Treating B-cell malignancies such as leukemias, lymphomas, and multiple myeloma often requires engaging multiple tumor antigens simultaneously to achieve effective immune-mediated killing. However, conventional monospecific antibodies and single-target bispecifics frequently fail to provide sufficient selectivity or potency, and multi-specific designs are difficult to engineer and screen efficiently.
Solution
MATCH offers a high-throughput platform for designing and screening bispecific antibody fragments that can simultaneously target multiple antigens on malignant B cells. The system integrates predictive computational modeling with rapid combinatorial generation of antibody binding fragments, enabling the production of any bispecific combination. This approach supports the creation of multi-specific T-cell engagers that improve T-cell activation while reducing cytokine release, as demonstrated in peer-reviewed studies. The platform has been validated in publications across ACS Nano, Nanomedicine, and Nature Communications Biology, confirming its ability to guide dosing and optimize therapeutic efficacy.
Target Audience
Primary users are oncology researchers and biopharmaceutical developers focused on creating next-generation T-cell engagers and multi-specific immunotherapies for B-cell leukemias, lymphomas, and multiple myeloma.
Features
- High-throughput combinatorial generation of bispecific antibody fragments from any pair of binding domains
- Predictive computational modeling to guide multi-specific design and dosing decisions
- Two-component T-cell engager architecture that enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy
- Platform validated in peer-reviewed studies across ACS Nano, Nanomedicine, and Nature Communications Biology
- Capable of producing any bispecific combination of antibody binding fragments for flexible targeting of B-cell malignancies